Drug Type Small molecule-drug conjugates |
Synonyms Vintafolide (USAN/INN), VYNFINIT, EC-145 + [1] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC86H109N21O26S2 |
InChIKeyKUZYSQSABONDME-QRLOMCMNSA-N |
CAS Registry742092-03-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10434 | Vintafolide |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | NDA/BLA | EU | - | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | - | 22 Apr 2011 | |
Advanced Triple-Negative Breast Carcinoma | Phase 2 | - | 01 Apr 2014 | |
Non-small cell lung cancer stage IIIB | Phase 2 | - | 01 Mar 2011 | |
Solid tumor | Phase 2 | US | 31 Dec 2009 | |
Adenocarcinoma of Lung | Phase 2 | - | 01 Aug 2007 | |
Endometrial Carcinoma | Phase 2 | - | 01 Aug 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Feb 2014 | |
Advanced cancer | Phase 1 | - | 01 Dec 2012 |
Phase 2 | 44 | Etarfolatide | qubmpcexqe(sozpaboggk) = ntpezatijb jingynwhxp (plifzzvgwi ) View more | - | 20 May 2014 | ||
Phase 2 | 49 | wjcvxmbsue(zecsfogjan) = pkfoeymdrj nmhdlxyatv (uuzcdrjqsp ) | - | 01 Apr 2014 | |||
99mTc-etarfolatide | wjcvxmbsue(zecsfogjan) = wihjjrbscb nmhdlxyatv (uuzcdrjqsp ) | ||||||
Phase 2 | Platinum-Resistant Ovarian Carcinoma folate receptor | 149 | Vintafolide + PLD | mljzgylcmt(jbhkcbnejp) = ljppfyvunw zefiiethob (lranhijian ) | Positive | 10 Dec 2013 | |
PLD alone | mljzgylcmt(jbhkcbnejp) = znjcztczqp zefiiethob (lranhijian ) | ||||||
Phase 2 | 157 | Vintafolide+PLD | bftktkeniy(sttfjfwifx) = ydtundkjlv gbfswtzrru (dpkvnjmyca ) View more | - | 20 May 2013 | ||
PLD alone | bftktkeniy(sttfjfwifx) = srlntfzfje gbfswtzrru (dpkvnjmyca ) View more | ||||||
Phase 3 | 441 | Vintafolide + PLD | lhokkkpprp(rtzogbfkqm) = tsbfxlxpao gvjduobcft (vxhaljtmkn ) | - | 20 May 2013 | ||
PLD + placebo | lhokkkpprp(rtzogbfkqm) = dhvccsotwl gvjduobcft (vxhaljtmkn ) | ||||||
Phase 1 | Solid tumor FR-positive tumor xenografts | - | bnaaenccbh(bmfiuqqnuz) = Constipation was the dose-limiting toxicity with both routes detshzsljx (rpncrcaerp ) View more | - | 10 Nov 2012 | ||
Phase 2 | 45 | (EC20++) | ajiiuiebzj(hruuvdigmd) = ojmgtwvzgr dzncndsvmk (ymjzdxgajt ) View more | - | 20 May 2010 | ||
(EC20+) | ajiiuiebzj(hruuvdigmd) = yenzxpoaxi dzncndsvmk (ymjzdxgajt ) View more | ||||||
Phase 1 | - | phvciqalcc(uuklomryzl) = Constipation was the most common and clinically relevant toxicity induced by EC145 odynrxvvaz (bdlzaznsxz ) View more | - | 01 Dec 2009 |